HOME >> MEDICINE >> NEWS
Study examined switching rates between Allegra® (fexofenadine HCl) and Claritin®

CHICAGO, Il., November 13, 1999 - A higher percentage of seasonal allergic rhinitis (SAR) patients switched to Allegra® (fexofenadine HCl) from Claritin® (loratadine) than vice versa in the spring and fall of 1997 and 1998, according to the results of a study of more than 33,000 patients presented at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI).

The findings are based on "Prescribing Patterns of Non-sedating Antihistamines and Daily Dose Differences in a Managed Care Population," a study that evaluated the continuity of allergy treatment by drug and by allergy season (spring, fall 1997- 1998). The retrospective study analyzed data from physicians' claims from 12 United Healthcare health plans.

During the study period, an average of 12.6 percent of patients taking Claritin switched to Allegra versus 10.0 percent of patients who switched from Allegra to Claritin. "Usage data about newer therapies is important for managed care organizations to analyze so they can understand physician and patient preferences," said Lewis Roht, M.D., Director of Drug Surveillance and Epidemiology at Hoechst Marion Roussel.

Other Studies
Other data presented at the ACAAI meeting by Hoechst Marion Roussel included:

  • A four-week, multicenter, double-blind, randomized, placebo-controlled study which showed that Allegra at doses of 20, 60, 120, and 240 mg reduced pruritus and number of wheals scores over a four-week period for the treatment of chronic idiopathic urticaria (CIU), also known as hives. The study demonstrated that all doses of Allegra greatly reduced the symptoms compared to placebo (P0.0115). Additionally, patients who received Allegra experienced significantly less interference with sleep and daily activities than patients who received placebo (P0.0014). Twice-daily doses of 60 mg or greater were most effective. Adverse events occurred with similar incidence in all treatment groups, with
    '"/>


Contact: Suzanne Wiele
816-966-3475
Porter Novelli
12-Nov-1999


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:8/28/2015)... Florida (PRWEB) , ... August 28, 2015 , ... ... holistic approach to medicine through health promotion and disease prevention, improving a patient’s ... most prevalent diseases in the community, including heart disease, cancer, diabetes, HIV/AIDS, STDs, ...
(Date:8/27/2015)... ... August 28, 2015 , ... Best-selling Author Vanessa Diffenbaugh, ... through “The Language of Flowers,” has joined the Youth Villages national board of ... YVLifeSet program, was piqued by her passion for helping foster youth. Her debut ...
(Date:8/27/2015)... ... 27, 2015 , ... Keck Graduate Institute (KGI), School of Pharmacy celebrated its ... a formal ceremony recognizing them as members of the 2nd class of the KGI ... Symbolizing dedication to clinical service and patient care, the White Coat Ceremony is held ...
(Date:8/27/2015)... Los Anegeles and Costa Mesa, CA (PRWEB) , ... August 27, ... ... revolving door, going in to get help, leaving weeks or months later, relapsing and ... by overdose or accidents under the influence while in sober living homes or soon ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article published ... Hernia Surgery involved many conversations between hernia experts surrounding the search for the ideal ... that many different experts have different ideas about which is the best mesh for ...
Breaking Medicine News(10 mins):Health News:Health Clinic Opening and Public Art Unveiling 2Health News:Best-selling Author Vanessa Diffenbaugh Joins Youth Villages National Board of Directors 2Health News:Best-selling Author Vanessa Diffenbaugh Joins Youth Villages National Board of Directors 3Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 3Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 4Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Recent Article on Hernia Mesh Developments Highlights Viable Options, But Shows a Need for Further Research, notes Dr. Shirin Towfigh 2
(Date:8/27/2015)... 2015  Mytrus, a technology and services company revolutionizing clinical trials, ... consent has received approval for use by ... the first time e-Consent technology will be used in ... Mytrus was also the first electronic informed ... by the U.S. Food and Drug Administration in 2011. ...
(Date:8/27/2015)... , Aug. 27, 2015  Lightwave Logic, ... the development of Next Generation Photonic Devices ... applications in high speed fiber-optic data communications and ... Lebby has been appointed to the Company,s ... in the field of optoelectronics is widely recognized ...
(Date:8/27/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... company serving the pharmaceutical, biotechnology, and medical ... and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., ... the Japan PMDA for the manufacture of ... drug in July. STA is now the ...
Breaking Medicine Technology:Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3WuXi PharmaTech's STA Subsidiary Receives First Approval from Japanese Regulatory Authorities 2
Cached News: